Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective.

LaPensee, Kenneth; Mistry, Rohit; Lodise, Thomas

LaPensee, Kenneth; Mistry, Rohit; Lodise, Thomas.

Afiliação

LaPensee K; Director, Health Economics and Outcomes Research, Paratek Pharmaceuticals, Inc, King of Prussia, PA.
Mistry R; Senior Associate, Health Economics, PAREXEL Access Consulting, PAREXEL International, London, UK.
Lodise T; Professor, Albany College of Pharmacy and Health Sciences, NY.

Am Health Drug Benefits ; 12(1-Supplement 1): S1-S12, 2019 Feb.

Article em En | MEDLINE | ID: mdl-30996766

Palavras-chave

bacterial pneumonia; budgetary impact; community-acquired bacterial pneumonia; economic model; omadacycline

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: Am Health Drug Benefits Ano de publicação: 2019 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google